Currently, personalized therapies that identify and target specific biomarkers have resulted in substantial benefits for NSCLC patients with EGFR mutations, gene alterations involving the anaplastic lymphoma kinase (ALK) gene, BRAF V600E mutation, or the ROS1 gene. The gene discussed is ALK; the disease is non-small cell lung carcinoma.